Determination of trace impurities in cosmetic intermediates by ion mobility spectrometry

The cosmetic and pharmaceutical industries are continuously demanding fast, efficient, cost-effective analytical methods to monitor production processes and assure end-product quality. The presence of residual reagents or impurities formed during a synthetic process can have an adverse impact on product quality, assurance of which requires using increasingly sensitive analytical methods to facilitate the detection and/or determination of toxic compounds with potentially hazardous effects on consumer's health. In this work, we assessed the potential of ion mobility spectrometry (IMS) for the detection and quantitation of dimethylaminopropylamine (DMAPA) residues in stearamidopropyldimethylamine (SAPDA) production samples. The influence of instrumental variables including solvent, solution drying time, injected volume and volatilization temperature was examined. The ensuing analytical method takes less than 1 min per analysis and uses only a few microlitres of sample. The calibration curve was linear over the DMAPA concentration range 0.030-0.500 μg mL(-1). The proposed method was validated for use in control processes. The complex plasmagram for amidoamines allows the origin of cosmetic oils to be easily, expeditiously identified. Based on the results, IMS holds great promise for the qualitative and quantitative determination of the studied amide and various others in cosmetic products.

The role of 3-dimethylaminopropylamine and amidoamine in contact allergy to cocamidopropylbetaine

Since it has been found that all subjects with contact allergy to cocamidopropylbetaine (CAPB) have positive reactions to 3-dimethylaminopropylamine (DMAPA), and reports have appeared in literature of the sensitizing action of amidoamine in products containing CAPB, we aimed to verify the possibility that pure amidoamine may have a sensitizing role in subjects with positive reactions to CAPB. To this end, in 10 patients with contact allergy to a commercial CAPB, we tested DMAPA 1% aq. and a pure amidoamine in concentrations ranging from 0.5% aq. to 0.1% aq. The study showed that all patients with positive reactions to DMAPA reacted to amidoamine at 0.5% and 0.25% aq., while 4 of the 10 also had positive reactions to amidoamine at 0.1% aq. We consider that simultaneous allergic reaction to DMAPA and amidoamine represents cross-reactivity and hypothesize that DMAPA is in fact the true sensitizing substance, while amidoamine, which may in any case release DMAPA in vivo as a result of enzymatic hydrolysis, may favour the transepidermal penetration of the sensitizing agent. In addition, we advise that testing of CAPB be suspended, because, as suggested by chemico-structural analyses and demonstrated in vivo, when thoroughly purified, it no longer has a sensitizing action.